ASCO’s “rock concert” moments came 17 years apart—in 2005 and 2022 DESTINY-04 results extend HER2-targeted therapy to a larger population in breast cancer

Radiation before mastectomy cuts time delays for reconstructive surgery in breast cancer patients

Researchers at MD Anderson Cancer Center showed that altering the sequence of breast cancer treatment to administer radiation before mastectomy allowed for concurrent breast reconstruction surgery, which reduced the number of operations required, minimized treatment delays, and improved patient satisfaction.

April 12, 2024

Vol.50 No.15

In Brief

Antonio Wolff named co-lead of NCI Breast Cancer Steering Committee

Antonio C. Wolff, chair of the Breast Cancer Committee for the ECOG-ACRIN Cancer Research Group, will co-lead the Breast Cancer Steering Committee for NCI. He began the three-year term on April 1.

April 05, 2024

Vol.50 No.14

Clinical Roundup

Study finds TNBC tumors with an increase in immune cells have lower risk of recurrence after surgery

A multicenter, international study suggests that people who have early-stage triple-negative breast cancer and high levels of tumor-infiltrating lymphocytes within their tumors may have a lower risk of recurrence and better survival rates, even when not treated with chemotherapy.

April 05, 2024

Vol.50 No.14

In the Archives

Women’s History Month—How “Dr. Susan Love’s Breast Book” has remained the “bible” for women with breast cancer since 1990

When Stephanie Graff was a breast oncology fellow in 2010, one of her patients brought a marked up copy of “Dr. Susan Love’s Breast Book” to an appointment.

March 29, 2024

Vol.50 No.13

By Alexandria Carolan

Clinical Roundup

UCLA: Adding ribociclib to hormone therapy reduces the risk of breast cancer recurrence

A novel treatment approach that combines a targeted therapy drug with hormone therapy significantly increased the amount of time a person with stage 2 or 3 HR-positive, HER2-negative early breast cancer lives without the cancer returning, according to a phase III trial co-led by UCLA Health Jonsson Comprehensive Cancer Center investigators.

March 29, 2024

Vol.50 No.13

In Brief

ASCO 2024 special awards go to: Winn, Bhatia, Dale, Siu, Pierce, Kantoff, Newman, Gopal, Mutebi, Feldman, Gorlick, Pietenpol, Abrahm, Giordano, Vaz-Luis

ASCO and Conquer Cancer, the ASCO Foundation, will recognize researchers, patient advocates, philanthropists, teachers, and global oncology leaders at the 2024 ASCO Annual Meeting.

March 22, 2024

Vol.50 No.12

ASCO’s “rock concert” moments came 17 years apart—in 2005 and 2022

DESTINY-04 results extend HER2-targeted therapy to a larger population in breast cancer

YOU MAY BE INTERESTED IN

Radiation before mastectomy cuts time delays for reconstructive surgery in breast cancer patients

Antonio Wolff named co-lead of NCI Breast Cancer Steering Committee

Study finds TNBC tumors with an increase in immune cells have lower risk of recurrence after surgery

Women’s History Month—How “Dr. Susan Love’s Breast Book” has remained the “bible” for women with breast cancer since 1990

UCLA: Adding ribociclib to hormone therapy reduces the risk of breast cancer recurrence

ASCO 2024 special awards go to: Winn, Bhatia, Dale, Siu, Pierce, Kantoff, Newman, Gopal, Mutebi, Feldman, Gorlick, Pietenpol, Abrahm, Giordano, Vaz-Luis

Renew today!

Subscriber content

Login